EGFR and colorectal carcinoma: The differential distribution of these genomic CRC subtypes and other biological features between right-sided and left-sided CRCs may contribute to the inferior prognosis of advanced-stage right-sided CRCs and poorer outcomes with anti-EGFR therapy in right-sided CRC [17].